EDAP TMS S.A. ADR | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
10,584.00
14,692.40
15,836.10
23,192.90
24,020.80
22,250.30
Total Accounts Receivable
12,943.10
9,854.60
12,778.10
10,574.90
14,820.30
15,224.50
Inventories
6,473.60
7,149.00
6,681.80
8,469.60
8,092.20
8,244.40
Other Current Assets
486.40
509.40
594.20
482.00
587.20
436.70
Total Current Assets
30,487.10
32,205.50
35,890.30
42,719.50
47,520.50
46,155.80
Net Property, Plant & Equipment
2,280.50
2,567.70
2,306.20
2,921.70
4,421.30
4,810.40
Long-Term Note Receivable
435.40
772.00
644.20
315.40
92.50
29.70
Intangible Assets
3,373.20
2,947.70
2,662.50
2,701.20
3,529.20
3,725.50
Other Assets
454.70
415.10
407.40
471.50
552.40
625.30
Total Assets
37,031.00
38,907.90
41,910.50
49,141.90
56,313.90
55,717.10
ST Debt & Current Portion LT Debt
3,420.10
2,975.50
3,542.40
2,179.10
4,029.90
Accounts Payable
7,489.20
6,661.30
6,624.30
6,286.30
7,577.00
Income Tax Payable
13.80
4.80
677.90
382.90
176.50
Other Current Liabilities
5,046.10
5,070.10
6,830.70
6,983.50
7,590.30
Total Current Liabilities
15,969.10
14,711.80
17,675.20
15,831.80
19,373.70
Long-Term Debt
5,589.00
3,374.80
962.50
735.20
1,635.50
Provision for Risks & Charges
2,615.30
2,241.00
2,224.70
2,723.40
3,172.50
Deferred Taxes
-
-
-
12.70
198.10
Other Liabilities
64.80
89.50
5,115.40
3,811.90
674.90
Total Liabilities
24,238.10
20,417.20
25,977.80
23,102.20
24,856.60
Common Equity (Total)
12,792.90
18,321.40
15,675.30
25,789.70
30,209.70
Total Shareholders' Equity
12,792.90
18,321.40
15,675.30
25,789.70
30,209.70
Total Equity
12,792.90
18,321.40
15,675.30
25,789.70
30,209.70
Liabilities & Shareholders' Equity
37,031.00
38,907.90
41,910.50
49,141.90
56,313.90
Non-Equity Reserves
-
169.40
257.50
250.00
1,247.60

About EDAP TMS

View Profile
Address
Parc d'Activités la Poudrette-Lamart
Vaulx-en-Velin Rhone-Alpes 69120
France
Employees -
Website http://www.edap-tms.com
Updated 07/08/2019
EDAP TMS SA develops, produces and markets minimally invasive medical devices for urological diseases. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment, Ablatherm-HIFU is approved and commercialized in Europe as a treatment for prostate cancer and is currently under regulatory review in the U.